Succinylcholine for Bronchospasm: Not Indicated
Succinylcholine is a neuromuscular blocking agent used to facilitate endotracheal intubation, not to treat bronchospasm itself. The drug provides muscle paralysis to enable airway management but does not possess bronchodilatory properties and may actually worsen bronchospasm in certain situations.
Role of Succinylcholine in Airway Management
Succinylcholine is indicated for rapid sequence intubation (RSI) to achieve muscle relaxation for endotracheal tube placement 1, 2. The drug:
- Does not provide sedation, analgesia, or amnesia 1
- Creates satisfactory intubation conditions within 30-45 seconds after IV administration 1
- Has a duration of action of approximately 5-10 minutes 1
- Should only be used by those skilled in airway management with immediate availability of ventilation equipment 2
Bronchospasm Considerations with Succinylcholine
Potential to Worsen Bronchospasm
Research demonstrates that succinylcholine can actually induce or worsen bronchospasm, particularly in patients with hyperreactive airways:
- In sensitized rabbits, succinylcholine caused the largest increases in airway resistance (146% ± 29%) compared to other neuromuscular blocking agents 3
- The bronchospasm develops via histamine release and muscarinic receptor interactions 4
- Allergic sensitization leads to severe and rapidly developing bronchospasm after succinylcholine administration 3
Clinical Context: Intubation in Status Asthmaticus
When patients with severe bronchospasm require intubation, succinylcholine may be used as part of RSI, but only to facilitate intubation, not to treat the bronchospasm:
- One case series showed improved respiratory acidosis after intubation using ketamine and succinylcholine in status asthmaticus patients, but the improvement was attributed to mechanical ventilation and ketamine's bronchodilatory effects, not succinylcholine 5
- Ketamine (not succinylcholine) provides bronchodilation and is recommended for induction in patients with bronchospasm 1, 5
Actual Treatment for Bronchospasm
For bronchospasm resistant to standard therapy, guidelines recommend 6:
- Inhaled β-agonists (nebulized albuterol 2.5-5 mg in 3 mL saline, repeated as necessary) 6
- Epinephrine as first-line therapy for severe bronchospasm/anaphylaxis 6
- Ipratropium bromide as adjunct therapy 1
- In refractory post-intubation bronchospasm, endotracheal epinephrine (0.5 mg of 1:10,000 in 10 mL normal saline) has been reported as effective 7
Alternative Neuromuscular Blocking Agents
When RSI is needed in patients with bronchospasm or hyperreactive airways:
- Rocuronium (1.0-1.2 mg/kg) should be used when succinylcholine is contraindicated 8, 9
- Rocuronium causes less bronchospasm than succinylcholine (40% ± 12% increase in airway resistance versus 146% ± 29%) 3
- Sugammadex should be immediately available when rocuronium is used 8, 10
- Recent guidelines suggest either rocuronium or succinylcholine can be used for RSI when no contraindications exist 9
Critical Safety Warnings
The FDA label emphasizes that succinylcholine 2:
- Should be administered with GREAT CAUTION to patients with electrolyte abnormalities due to hyperkalemia risk
- Must only be used when facilities for tracheal intubation and ventilation are immediately available
- Can cause severe anaphylactic reactions that may be life-threatening
- Should be reserved for emergency intubation in pediatric patients (e.g., laryngospasm, difficult airway) 2
Common Pitfall
The critical error is confusing succinylcholine's role in facilitating intubation with treating the underlying bronchospasm. Succinylcholine paralyzes muscles to allow tube placement, but the bronchospasm itself requires specific bronchodilator therapy (β-agonists, epinephrine, anticholinergics) 6, 1.